综述 |
|
|
|
|
溶瘤腺病毒靶向癌症治疗的临床研究进展 |
周立, 何婉婉, 朱桢楠, 杨远勤, 赵红芳, 马步云, 王毅刚 |
浙江理工大学生命科学学院新元医学与生物技术研究所 杭州 310018 |
|
The Clinical Research Progress for Oncolytic Adenovirus Targeting Cancer Therapy |
ZHOU Li, HE Wan-wan, ZHU Zhen-nan, YANG Yuan-qin, ZHAO Hong-fang, MA Bu-yun, WANG Yi-gang |
Xinyuan Institute of Medicine and Biotechnology, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China |
引用本文:
周立, 何婉婉, 朱桢楠, 杨远勤, 赵红芳, 马步云, 王毅刚. 溶瘤腺病毒靶向癌症治疗的临床研究进展[J]. 中国生物工程杂志, 2013, 33(12): 105-113.
ZHOU Li, HE Wan-wan, ZHU Zhen-nan, YANG Yuan-qin, ZHAO Hong-fang, MA Bu-yun, WANG Yi-gang. The Clinical Research Progress for Oncolytic Adenovirus Targeting Cancer Therapy. China Biotechnology, 2013, 33(12): 105-113.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/
或
https://manu60.magtech.com.cn/biotech/CN/Y2013/V33/I12/105
|
[1] Smith R R, Huebner R J, Rowe W P, et al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer, 1956, 9(6): 1211-1218. [2] Southam C M. Division of microbiology: present status of oncolytic virus studies. Transactions of the New York Academy of Sciences, 1960, 22(8 Series Ⅱ): 657-673. [3] 胡泽斌. 溶瘤腺病毒载体系统的构建及其功能研究. 中国人民解放军军事医学科学院, 2008. Hu Z B.Construction and function study of oncolytic adenovirus vector system, the Academy of Military Medical Sciences of the Chinese PLA, 2008. [4] 蒋泓, 刘芳, 严爱芬, 等. 溶瘤病毒的肿瘤治疗作用研究. 佛山科学技术学院学报 (自然科学版), 2013, 31(2):1-6. Jiang H, Liu Fang, Yan A F, et al.The application of oncolytic virus to cancer therapy.Journal of Foshan University(Natural Science Edition), 2013, 31(2):1-6. [5] Liu X, Cao X, Wei R, et al. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Cancer Gene Terapy, 2011, 19(1): 49-57. [6] Ranki T, Kanerva A, Ristimki A, et al. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5. pk7-Δ24, for the treatment of advanced breast cancer. Gene Therapy, 2006, 14(1): 58-67. [7] 徐凯, 诸琦. 溶瘤病毒的临床应用. 生物医学工程与临床, 2008, 12(4): 347-350. Xu K, Zhu Q.Clinical application of oncolytic virus.Biomedical Engineering and Clinical Medicine, 2008, 12(4): 347-350. [8] 谭晓华. 溶瘤腺病毒肿瘤靶向治疗: 从实验室到临床. 中国肿瘤生物治疗杂志, 2012, 19(006): 569-576. Tan X H.Oncolytic adenovirus for targeted cancer therapy:from laboratory to the clinic.Chinese Journal of Cancer Biotherapy, 2012, 19(006): 569-576. [9] 王毅刚, 黄芳, 蔡荣, 等. 腺相关病毒载体的靶向策略探讨. 科学通报, 2007, 52(10): 1107-1115. Wang Y G, Huang F, Cai R, et al.A discussion on adenovirus-associated virus vector.Chinese Science Bulletion, 2007, 52(10): 1107-1115. [10] Li Y, Idamakanti N, Arroyo T, et al. Dual promoter-controlled on-colytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.Clin Cancer Research, 2005, 11(24 Pt 1): 8845-8855. [11] Zou W, Luo C, Zhang Z, et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene, 2004, 23(2): 457-464. [12] Kamizono J, Nagano S, Murofushi Y, et al. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication. Cancer Research, 2005, 65(12): 5284-5291. [13] Tiemann K, Rossi J J. RNAi‐based therapeutics–current status, challenges and prospects. EMBO Molecular Medicine, 2009, 1(3): 142-151. [14] 仲苏阳. 靶向性基因-病毒疗法联合化学药物治疗肿瘤的研究. 浙江理工大学, 2008. Zhong S Y.Combination of targeting gene-virotherapy and chemotherapy.Zhejiang Sci-Tech University, 2008. [15] Pilankatta R, Chawla T, Khanna N, et al. The prevalence of anti-bodies to adenovirus serotype 5 in an adult indian population andimplications for adenovirus vector vaccines.J Med Virol, 2010, 82(3): 407-414. [16] Willmon C, Harrington K, Kottke T, et al. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.Mol Ther, 2009, 17(10): 1667-1676. [17] Brummelkam PT R, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells.Science, 2002, 296(5567): 550-553. [18] Bessard A, Frémin C, Ezan F, et al. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene, 2008, 27(40): 5315-5325. [19] Wang Y H, Liu S, Zhang G, et al. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo.Breast Cancer Res, 2005, 7(2):220-228. [20] Chu L, Gu J, Sun L, et al. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Gene Ther, 2008, 15:484-494. [21] Zheng J N, Ma T X, Cao J Y, et al. Knockdown of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells. Life Sciences, 2006, 78(7): 724-729. [22] 陈家存, 郑骏年, 毛立军, 等. 表达 Ki67 基因小干扰 RNA 的选择性增殖溶瘤腺病毒的构建. 中华实验外科杂志, 2006, 23(7): 849-852. Cheng J C, Zheng J N, Mao L J, et al.Construction and identification of replication selective oncolytic adenovirus expressing short interferenee RNA targeting Ki67gene.Chinese Journal of Experimental Surgery, 2006, 23(7): 849-852. [23] 潘秋卫, 蔡荣, 刘新垣, 等. 肿瘤基因治疗新策略——RNA 干扰. 科学通报, 2006, 51(9): 993-997. Pan Q W, Cai R, Liu X Y, et al.A novel strategy in cancer gene therapy:RNAi.Chinese Science Bulletin, 2006, 51(9): 993-997. [24] 王卫芸, 顾锦法, 戴平, 等. 双靶向溶瘤腺病毒 MD55 对肿瘤细胞与正常细胞的杀伤作用比较. 细胞生物学杂志, 2008, 30(5): 635-641. Wang W Y, Gu J F, Dai P, et al.Selective cytotoxic effect of dual tumor-targeting oncolytic adenovirus MD55 on tumor and normal cells in vitro.Chinese Journal of Cell Biology, 2008, 30(5): 635-641. [25] 张唯, 张红锋. 双靶向溶瘤腺病毒对肿瘤细胞及正常细胞的杀伤差异性研究. 华东师范大学学报(自然科学版), 2007, 6:112-119. Zhang W, Zhang H F.Difference of killing effects of dual-targeting oncolytic adenovirus on tumor and normal cells.Journal of East China Normal University(Natural Science), 2007, 6:112-119. [26] 王娟, 顾锦法, 杨水云, 等. 癌特异性双靶向载体的安全性及其携带基因的杀伤性.癌症, 2006, 25(4): 385-392. Wang J, Gu J F, Yang S Y, et al, Security of dual cancer-specific targeting vector and its cytotoxic effect when harbored.Chinese Journal of Cancer, 2006, 25(4): 385-392. [27] 曾祯, 刘新垣. 携带TRAIL和IL-24的双基因三靶向溶瘤腺病毒构建及其抗癌效果的研究. 中国科技论文在线, http://www.paper.edu.cn/releasepaper/content/201202-830. Zeng Z, Liu X Y. Triple-regulated oncolytic adenovirus mediates coexpression of TRAIL and IL-24 linked by IETD sequence.Science Paper Online, http://www.paper.edu.cn/releasepaper/content/201202-830. [28] Liu X R, Cai Y, Cao X, et al. A new oncolytic adenoviral vector carrying dual tumour suppressor genes shows potent anti‐tumour effect. Journal of Cellular and Molecular Medicine, 2012, 16(6): 1298-1309. [29] 刘佳, 马蕾娜, 王毅刚, 等. 癌症治疗新思路: 靶向肿瘤干细胞. 科学通报, 2008, 53(9): 1003-1009. Liu J, Ma L N, Wang Y G, et al, Novel strategy in cancer treatment:targeting cancer stem cell. Chinese Science Bulletin, 2008, 53(9): 1003-1009. [30] 张金龙, 钱海利, 林晨, 等. 肿瘤干细胞靶向治疗研究进展. 中国医药生物技术, 2010, 5: 371-373. Zhang J L, Qiang H L, Lin C, et al. Progression in cancer stem cell targeted therapy.Chinese Medicinal Biotechnology, 2010, 5: 371-373. [31] Jiang H, Gomez-Manzano C, Aoki H, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. Journal of the National Cancer Institute, 2007, 99(18): 1410-1414. [32] John W, Son L. Gene Therapy Clinical Trials Worldwide:http://www.abedia.com/wiley/vectors.php. [33] 张璐, 林军, 郑玉果, 等. 病毒与肿瘤发生及治疗的关系. 世界临床药物, 2012, 33(006): 375-379. Zhang L, Lin J, Zheng Y G, et al, Role of virus in the tumor genesis and treatment. World Clinical Drugs, 2012, 33(006): 375-379. [34] 胡放, 胡晓桦, 余萍, 等. 溶瘤病毒 H101 结合局部加热治疗对转移肿瘤病灶的远端效应. 癌症, 2006, 25(8): 919-924. Hu F, Hu X H, Yu P, et al.Abscopal effect on metastatic tumor induced by oncolytic virus of H101 combining with local heating.Chinese Journal of Cancer, 2006, 25(8): 919-924. [35] 施静, 刘燕飞. 特异性溶瘤重组腺病毒 Ⅰ 期临床试验受试者的观察. 上海护理, 2010, 10(003): 66-68. Shi J, Liu Y F. The observation of clinical phase I of specific oncolytic recombinant adenovirus in subjects. Shanghai Nursing, 2010, 10(003): 66-68. [36] Nie Z L, Pan Y Q, He B S, et al. Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system. Molecular Cancer, 2012, 11(1): 86. [37] Li Y, Li W G, Zhang J S.Recombinant Ad5 interventional treatment of malignant tumors of route safety study. Shanghai Medical & Pharmaceutical Journal, 2013; 34(1):24-26. [38] Vh-Koskela M J, Heikkil J E, Hinkkanen A E. Oncolytic viruses in cancer therapy. Cancer Letters, 2007, 254(2): 178-216. [39] 蒋冠, 刘彦群, 郑骏年. 溶瘤腺病毒联合化疗治疗肿瘤的研究. 国际肿瘤学杂志 ISTIC, 2008, 35(9):647-650. Jiang G, Liu Y Q, Zheng J N.Oncolytic adenouiruses in combination with chemtherapy in tumor therapy. Journal of International Oncology, ISTIC, 2008, 35(9):647-650. [40] Galanis E, Okuno S H, Nascimento A G, et al.Phase I-Ⅱ trial of ONYX.015 in combination with MAP chemotherapy in patients with advanced sarcomas.Gene Ther, 2005, 12(5):437-445. [41] Yoon A R, Kim J H, Lee Y S, et al.Markedly enhanced cytolysis byE1 B-19kD deleted oncolytic adenovirus in combination with cisplatin.Hum Gene Ther, 2006, 17(4):379-390. [42] Qiu S, Ruan H, Pei Z, et al.Combination of targeting gene-virotherapy with 5-FU enhances antitumor efficacy in malignant eoloree-tal carcinoma. J Interferon Cytokine Res, 2004, 24(4):219-230. [43] Quirin C, Mainka A, Hesse A, et al.Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells.Int J Cancer, 2007, 121(12):2801-2807. [44] 郭科妮, 卓玲燕, 刘涛, 等. 携带 TSLC1 基因的双靶向溶瘤腺病毒联合阿霉素对 SMMC-7721 肝癌细胞的杀伤作用. 中国细胞生物学学报, 2013, 35(3): 282-289. Guo K N, Zhuo L Y, Liu T, et al. Killing effect to hepatoma cell SMMC-7721 by dual-regulated oncolytic adenovirus-mediated TSLC1 combined with adriamycin.Chinese Journal of Cell Biology, 2013, 35(3): 282-289. [45] Kaliberova L N, Krendelchtchikova V, Harmon D K, et al.CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene Ther, 2009, 16:794-805. [46] Kangasniemi L, Parviainen S, Pisto T, et al. Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer. International Journal of Cancer, 2012, 131(1): 253-263. [47] Song X, Wang H, Jia R, et al. Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells. International Journal of Molecular Sciences, 2012, 13(9): 10736-10749. [48] Small E J, Carducci M A, Burke J M, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther, 2006, 14: 107-117. [49] Freytag S O, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res, 2002, 62: 4968-4976. [50] Russell S J, Peng K W, Bell J C. Oncolytic virotherapy. Nature Biotechnology, 2012, 30(7): 658-670. [51] Russell W C. Update on adenovirus and its vectors. J Gen Virol, 2000, 81(11): 2573-2604. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|